Market Place
Sourcing Support
CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China
04 Apr 2024 //
BIOSPECTRUM ASIA
Incyte and CMS Announce Collab and License Agreement for Povorcitinib in Asia
01 Apr 2024 //
BUSINESSWIRE
Incyte`s oral Dupixent rival hits in midphase skin disease trial
12 Mar 2024 //
FIERCE BIOTECH
Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
10 Mar 2024 //
BUSINESSWIRE
Data From Incyte’s Povorcitinib Clinical Program to Be Featured
13 Oct 2023 //
BUSINESSWIRE
Incyte Announces Positive 52-Week Data from Phase 2b Evaluating Povorcitinib
11 Oct 2023 //
BUSINESSWIRE
Incyte touts mid-stage data for JAK inhibitor but stops short of selecting PIII dose
21 Mar 2023 //
ENDPTS
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib
18 Mar 2023 //
BUSINESSWIRE
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib
10 Feb 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.